文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

局部碳酸酐酶抑制剂长期治疗青少年X连锁视网膜劈裂症

TOPICAL CARBONIC ANHYDRASE INHIBITORS IN THE LONG-TERM TREATMENT OF JUVENILE X-LINKED RETINOSCHISIS.
PubMed 文献 · Retina · 2022-01-01

回顾性干预病例系列纳入经基因确诊的青少年X连锁视网膜劈裂症患者10例18眼,接受2%多佐胺滴眼液每日2至3次双眼治疗,平均随访8.38年。中央子场厚度从基线429.88微米降至最终372.28微米(P=0.10),logMAR视力从0.45改善至0.34(P<0.01),未见副作用。

要点

  • 平均随访8.38年,为目前局部碳酸酐酶抑制剂治疗青少年X连锁视网膜劈裂症最长随访系列。
  • 中央子场厚度从基线429.88微米降至最终372.28微米,差异未达统计学显著(P=0.10)。
  • logMAR视力从基线0.45改善至最终0.34,差异有统计学意义(P<0.01),无患者出现局部多佐胺副作用。

核心结论

  • 研究数据支持既往关于X连锁视网膜劈裂症患者接受局部多佐胺治疗后视力改善的报告。
  • 这是迄今青少年X连锁视网膜劈裂症患者接受局部碳酸酐酶抑制剂治疗随访时间最长的系列。
  • 需要大规模前瞻性随机临床试验来提供关于局部碳酸酐酶抑制剂疗效更强证据。

研究设计与样本

  • 回顾性干预病例系列,纳入2005年至2021年在Cleveland Clinic Cole Eye Institute(三级转诊中心)经基因确诊的青少年X连锁视网膜劈裂症患者10例18眼。
  • 患者接受2%多佐胺滴眼液每日2至3次双眼治疗,2眼因视网膜脱离被排除。
  • 主要结局指标为最小分辨角对数视力与基于光学相干断层扫描的中央子场厚度。

主要发现

  • 平均随访8.38年(标准差3.41年)。
  • 中央子场厚度基线均值429.88微米(标准差143.36微米),最终均值372.28微米(标准差147.13微米),P=0.10。
  • logMAR视力基线均值0.45(标准差0.17),最终均值0.34(标准差0.22),P<0.01。
  • 无患者出现局部多佐胺副作用。

关键数值与推荐

  • 局部2%多佐胺滴眼液每日2至3次双眼治疗。
  • 中央子场厚度基线429.88微米(标准差143.36微米)对比最终372.28微米(标准差147.13微米),P=0.10。
  • logMAR视力基线0.45(标准差0.17)对比最终0.34(标准差0.22),P<0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the response to long-term topical dorzolamide treatment in patients with juvenile X-linked retinoschisis and cystic-like foveal lesions. METHODS: This was a retrospective interventional case series that included 18 eyes of 10 patients with genetically confirmed juvenile X-linked retinoschisis examined at the Cleveland Clinic Cole Eye Institute, a tertiary referral center, between 2005 and 2021. Patients were treated with topical 2% dorzolamide two to three times daily in both eyes. Two eyes were excluded because of retinal detachment. Primary outcome measures were logarithm of minimum angle of resolution visual acuity and optical coherence tomography based central subfield thickness. RESULTS: The mean follow-up was 8.38 years (SD, 3.41 years). The mean baseline and final central subfield thickness was 429.88 µ m (SD, 143.36 µ m) and 372.28 µ m, respectively (SD, 147.13 µ m, P = 0.10). The mean baseline and final logarithm of minimum angle of resolution visual acuity was 0.45 (SD, 0.17) and 0.34, respectively (SD, 0.22, P < 0.01). None of the patients experienced any side effects from topical dorzolamide. CONCLUSION: The study data support previous reports of improved visual acuity in X-linked retinoschisis patients on topical dorzolamide treatment. This is the longest follow-up for a series of juvenile X-linked retinoschisis patients treated with a topical carbonic anhydrase inhibitor to date. A large, prospective, randomized clinical trial is needed to provide stronger evidence regarding the efficacy of topical carbonic anhydrase inhibitors in juvenile X-linked retinoschisis.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Schmitt MA, Wang K, DeBenedictis MJ, et al. TOPICAL CARBONIC ANHYDRASE INHIBITORS IN THE LONG-TERM TREATMENT OF JUVENILE X-LINKED RETINOSCHISIS. Retina. 2022. PMID: 35982512. doi:10.1097/IAE.0000000000003588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。